NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Alfa Cytology's Next-Gen PrimePDX™ Platform for Enhanced Preclinical Cancer Modeling
TL;DR
Alfa Cytology's PrimePDX™ platform gives researchers an advantage by providing more accurate preclinical immunotherapy testing, potentially accelerating drug development timelines.
PrimePDX™ integrates human PBMCs into PDX models to create functional immune systems in mice, enabling detailed monitoring of tumor-immune interactions and treatment effects.
This technology improves preclinical cancer research accuracy, potentially leading to more effective immunotherapies that could save lives and reduce treatment side effects.
Scientists can now study cancer immunotherapies using mice with human-like immune systems, watching tumors and immune cells interact in real time.
Found this article helpful?
Share it with your network and spread the knowledge!
The platform addresses the challenge that many traditional tumor models do not fully reproduce immune responses, making it difficult to predict how treatments will behave in preclinical testing, particularly in immuno-oncology research.
PrimePDX™ adds human PBMCs to create a functional immune system in mice, uses small tumor fragments or early-passage tissues (P2–P5) to maintain tumor structure and diversity, and can include human CAFs to reproduce key features of the tumor microenvironment.
The platform is suitable for testing checkpoint inhibitors, antibody therapies, cell therapies, cancer vaccines, and other immune-based treatments.
Researchers can first screen treatments using Alfa Cytology's in vitro platforms, then confirm effects in PrimePDX™ animal models, and finally evaluate whether effects observed in lab studies are consistent in animal models.
Tumor growth and immune reconstitution are monitored throughout studies, and optional IVIS imaging allows non-invasive tracking of tumor progression.
Accurate immune response models are crucial for improving study designs, evaluating combination approaches, and making more confident decisions before further preclinical testing in immuno-oncology research.
Alfa Cytology develops in vitro and in vivo models including cell line-derived models, 3D cultures, cancer type-specific panels, and multiple animal models for drug testing, treatment mechanism studies, target validation, drug distribution assessment, and resistance tracking.
More information is available at https://www.alfacytology.com/primepdxtm-next-gen-pdx-for-clinical-simulation.html.
Alfa Cytology provides a wide range of cancer research models and preclinical testing services covering in vitro platforms, in vivo systems, and functional testing technologies to support tumor biology studies, drug evaluation, and immunotherapy research.
Curated from 24-7 Press Release
